MacroGenics, Inc. (NASDAQ: MGNX) is a Healthcare company (Biotechnology) with a market capitalization of $131M. The Maz Rating grades it against the other companies in its sector.
MacroGenics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.05, MacroGenics, Inc. trades at 1.2x sales and 5.2x book value. Over the last twelve months it generated about $113M of revenue and a net loss of $52M. It runs a gross margin of 4.2%, an operating margin of -70.2% and a net margin of -45.4%. It shows return on equity of -142.2%, return on invested capital of -13.6% and a free cash flow yield of -31.6%. On the balance sheet: a debt-to-equity ratio of 1.39 and a current ratio of 2.75. Over the past 52 weeks the share price ranged from $1.32 to $5.08, with a beta of 1.32.
MacroGenics, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 12 Buy, 9 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MacroGenics, Inc. (MGNX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 130.8% / 30% · Interest income / Revenue 15.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 130.8% / 33% · Receivables / Mkt Cap (36m) 0.87% / 49% · Interest income / Revenue 15.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 130.8% / 33.33% · Receivables / Mkt Cap (24m) 0.87% / 33.33% · Interest income / Revenue 15.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 12.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 70.7% / 33.33% · Receivables / Avg Assets (4Q) 14.9% / 33.33% · Interest income / Revenue 15.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 90.3% / 33.33% · (Cash+Recv) / Total Assets 90.9% / 33.33% · Interest income / Revenue 15.6% / 5% | Fail |
No. As of September 2026, MacroGenics, Inc. (MGNX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MacroGenics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 15.6% of each dividend: MacroGenics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.